<DOC>
	<DOCNO>NCT00097500</DOCNO>
	<brief_summary>This Phase 3 , open-label , multicenter study design compare effect exenatide insulin glargine ( LantusÂ® injection ) beta-cell function patient type 2 diabetes mellitus use metformin .</brief_summary>
	<brief_title>Effects Exenatide Insulin Glargine Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis type 2 diabetes , otherwise healthy HbA1c 6.6 % 9.5 % , inclusive . Body mass index ( BMI ) 25 kg/m2 40 kg/m2 , inclusive . Treated stable dose metformin least 2 month prior screen . Patients previously study use exenatide . Treated oral antidiabetic medication metformin within 2 month screen ( thiazolidinediones within 5 month screen ) . Treated insulin within 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>